No hay productos en el carrito



Treating Urothelial Bladder Cancer
Soria, F. — Gontero, P.
1ª Edición Agosto 2018
Inglés
Tapa dura
223 pags
400 gr
15 x 23 x 2 cm
ISBN 9783319785585
Editorial SPRINGER
LIBRO IMPRESO
-5%
51,99 €49,39 €IVA incluido
49,99 €47,49 €IVA no incluido
Recíbelo en un plazo de
2 - 3 semanas
LIBRO ELECTRÓNICO
-5%
88,39 €83,97 €IVA incluido
84,99 €80,74 €IVA no incluido
Acceso On Line
Inmediato
Preface.- Part I: Bladder cancer diagnosis.- Imaging and bladder cancer: can we do better?.- Optical improvements in bladder cancer diagnosis: seeing better for a better management.- Enhancing the quality of transurethral resection: the importance of a complete TURB and the en-bloc resection.- Active surveillance for low risk non-muscle invasive bladder cancer.- Part II: Non-muscle invasive bladder cancer.- How good we are to predict the outcomes of non-muscle invasive bladder cancer?.- Adjuvant treatment: old and new immunotherapy in non-muscle invasive bladder cancer.- The role of new experimental conservative therapies for high risk non-muscle invasive bladder cancer. Could we trust them?.- Part III: Muscle invasive bladder cancer.- Is there still a role for radical cystectomy?.- Minimally invasive radical cystectomy and its role in the treatment of bladder cancer patients. Myth or reality?.- Neoadjuvant vs adjuvant chemotherapy: which is right?.- Radiotherapy for the treatment of muscle invasive bladder cancer.- Immunotherapy and new combinations.- Part IV: A view on the future.- The role of urologist.- The role of pathologist.- The role of medical oncologist.- The role of radiotherapist.
This book aims to bring together the current research and discussions surrounding bladder cancer management. New technologies and therapeutic agents have become increasingly effective at treating urothelial bladder cancer and have created a range of opportunities to change the ways in which the disease is treated. Chapters cover the changes in adjuvant treatment, confocal laser endomicroscopy, and the roles of oncologists, pathologists, and radiotherapists in managing bladder cancer.
Treating Urothelial Bladder Cancer is particularly relevant to urologists, oncologists, and radiotherapists, but is also applicable to practitioners, geriatricians, and public health managers due to its multidisciplinary approach to bladder cancer management.
Paolo Gontero is Associate Professor of Urology at the University of Torino, Italy and currently Chairmen of the Division of Urology, San Giovanni Battista Hospital, Torino, Italy. His main clinical interests are Oncology Urology Surgery, Laparoscopic and Robotic kidney and prostate oncological surgery and Reconstructive Urology. He has authored and co-authored more than 200 publications on international journals.
Francesco Soria is Consultant Urologist at University of Vienna (Urologist, MD, FEBU).
© 2025 Axón Librería S.L.
2.149.0